This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Juvisync

Merck & Co., Inc.

Drug Names(s): MK-0431D, Januvia (sitagliptin, MK-0431) combined with Zocor (simvastatin), Juvicor (name not accepted by FDA)

Description: MK-0431D is a fixed dose combination of Januvia (sitagliptin) and simvastatin (branded drug Zocor).

Deal Structure: In June 2004, OSI acquired a portfolio of medical use patents relating to DPIV from Probiodrug. This portfolio contains a number of patent families comprising issued and pending patents and patent applications with claims relating to the use of DPIV inhibitors for the treatment of diabetes and related indications. OSI also licensed sub-licensable rights to patents and patent applications claiming combinations of DPIV inhibitors with other oral anti-diabetic drugs such as metformin. Its rights to this patent estate provide it with a source of upfront payments, and milestone and royalty revenue through the issuance of non-exclusive licenses to the patent estate. Merck has taken a license to this patent estate.

Ono and Merck
In November 2004, Merck granted Ono co-development and co-marketing rights to MK-0431, which is also to be developed and marketed by Banyu Pharmaceutical, Mercks subsidiary in Japan. Merck will supply MK-0431 to Ono as unpackaged product.

Astellas...See full deal structure in Biomedtracker

Partners: Royalty Pharma AG Ono Pharmaceutical Company, Ltd. Otsuka Holdings Co., Ltd.


Juvisync News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug